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Schizophrenia continues to pose a serious challenge to neuroscience and psychiatry as well as to
health care systems and to the patients and families who suffer this terrible and disabling
illness. Major developments in the past few months in both genetics and drug development
oblige us to consider novel drug discovery tactics for future schizophrenia research. Here we
review what we consider to be the key issues and some suggested solutions.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Death by a thousand variants: How
genetics has fundamentally altered our
understanding of schizophrenia
In October, Nature Genetics published the results of the
latest genome-wide association study (GWAS) of schizophre-
nia with close to 60,000 probands and controls (Ripke et al.,
2013). No common genetic variant that contributed any
meaningful effect was found, nor has anyone expected to
ﬁnd such a variant since the ﬁrst phase of schizophrenia
GWAS were published several years ago (Need et al., 2009;
Purcell et al., 2009; Shi et al., 2009; Stefansson et al., 2009)
The authors found 22 independent genetic loci that weakly
but signiﬁcantly associated with schizophrenia and used
these data to calculate that around 8000 independent SNPs
may collectively be able to explain about half of the genetic
contribution to schizophrenia. The remaining hope for GWAS.012
evier B.V. This is an open access article un
ac.uk (D.J. Nutt),is that some of these thousands of SNPs will implicate genes
that converge on a few speciﬁc and informative pathways.
Convergence on informative pathways is now the residual
ambition for schizophrenia sequencing studies as well.
An early exome sequencing study ruled out a large contri-
bution from genetic variants of intermediate frequency
(Need et al., 2012), but left open the possibility that a
modest number of genes could be important. This hope was
just dampened by two much bigger exome sequencing studies
published in Nature that failed to ﬁnd signiﬁcance support for
any individual genes (Fromer et al., 2014; Purcell et al.,
2014). Although sequencing studies involving tens of thou-
sands of schizophrenia patients will (hopefully) begin to
implicate individual genes, they will each be relevant to
only a very small fraction of schizophrenia cases.
From an etiological point of view, these studies showed
an exciting convergence: all three showed a suggestive
enrichment of signals from calcium channel genes and both
exome sequencing studies implicate the postsynaptic ARC
complex. Unfortunately, while these pathways include
tractable drug targets, their ubiquity in the brain means
that they are not likely to lead to drugs that are selectiveder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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implicated by genetic studies of bipolar disorder (Ferreira
et al., 2008) and there is some evidence that the calcium
channel blocker verapamil may be effective as an add-on
treatment resistant bipolar disorder (Mallinger et al., 2008).
However, calcium channels have critical roles in the devel-
oping brain and since prevention of schizophrenia may need
early pre-puberty interventions, effective drugs for schizo-
phrenia based on calcium channel antagonism may prove
impossible to develop with an acceptable safety margin.
There are some other important aspects of these ﬁndings.
For example some of the most exciting earlier “discoveries”
of genes for schizophrenia such as dysbindin and neuregulin
(Owen et al., 2005) have not replicated in larger studies,
and there is no evidence that variation in genes in the
dopamine system (including the infamous COMT) have any
role in schizophrenia. This is a real paradox given that the
only drugs that work in the disease are those that block
dopamine D2 receptor (DRD2) actions (Kapur and Mamo,
2003). Additionally, where genetic variants have reliably
been associated with schizophrenia, either through analysis
of copy number variants (CNVs) or very large GWAS, they
have indicated a shared genetic etiology across a wide range
of brain disorders including schizophrenia, ADHD, bipolar
disorder, autism, and intellectual disability (Cross-Disorder
Group of the Psychiatric Genomics et al., 2013; Grayton
et al., 2012).2. The end of the age of glutamate?
The second recent disappointment in schizophrenia
research is the failure of the two phase 3 trials of bitopertin
(Grogan, 2014). This is a Roche drug that works to enhance
the function of the excitatory neurotransmitter glutamate
at the NMDA receptor. A body of preclinical and human
postmortem studies has implicated deﬁcient glutamate
function, particularly in the prefrontal cortex in aspects of
schizophrenia, especially cognition and negative symptoms.
Glutamate is far too activating a neurotransmitter to be
directly mimicked or potentiated in the brain as anxiety and
then seizures are produced. To overcome this obstacle
allosteric modulators such as bitopertin and organon 25935
(Christmas et al., 2014) have been developed that more
subtly increase glutamate receptor function by increasing
the availability of glycine in the synaptic cleft. As glycine is
a glutamate potentiator, more glycine means more efﬁcacy
of glutamate at the NMDA receptor.
Glycine reuptake blockers are safe in humans and a phase
2 trial of bitopertin showed promise as an add-on in schizo-
phrenia (Stein, 2012). However the failure of the two phase
3 regulatory trials almost certainly means that this drug will
not now become a medicine. Moreover, the failure of this
major body of work, coupled with the fact that drugs working
on other glutamate receptors such as the Lilly metabotropic
receptor agonist pomaglumetad methionil (Heimer, 2012)
have also failed to show efﬁcacy in phase 3 studies after
promising phase 2 results, is likely to have a very deleterious
effect on the conﬁdence of other pharmaceutical companies
to stay in – let alone enter – this ﬁeld. Given the highly
signiﬁcant pull out from the psychiatry sector in recent years
(Nutt and Goodwin, 2011) this could mark the death-knell forpharmaceutical investment in new treatments for psychiatric
disorders.
The bitopertin story shows that developing new drugs
based on a theory is very risky. This issue of target speciﬁcity
in brain drug development is the leading challenge to this
ﬁeld today and the source of great hubris to the neuroscien-
tiﬁc ﬁeld. In the past 30 years there has not been a single
drug developed based on a new theory of psychopharmacol-
ogy; indeed one could argue that in the whole history of
psychiatry there have been no conceptual treatment break-
throughs based on neuroscience insights. The drugs we have
today are all reﬁnements of those discovered in the 1950s by
serendipity. Wherever drug targeting tests a theory it has
failed. Another major example other than the glutamate
drugs in schizophrenia has been the failure of amyloid-
reducing drugs e.g. bapineuzumab, in Alzheimer’s disease
(Wasilewski and Rose, 2012).
3. How to remedy the situation?
There are many exciting possible directions for developing
new schizophrenia treatments but we must be carefully
guided by our past successes and failures. There are two
unequivocal successes in schizophrenia treatment—that
dopamine D2 receptor blocking drugs are effective for some
symptoms in a proportion of patients and that clozapine has
special efﬁcacy in the more severely ill, treatment resistant
patients (Kane et al., 1988). Both facts were discovered by
serendipity. The dopamine receptor blocking discovery has
been successfully utilized but may offer more (Schmidt
et al., 2012), clozapine has proved impossible to improve on
largely because its special properties are still not
understood.
4. Improve current medications
Given the apparent genetic heterogeneity of schizophrenia,
it is very unlikely that one drug will ﬁx all. Indeed it is
remarkable that any drugs can be shown to work on as many
people as they do! Dopamine receptor blocking drugs help a
signiﬁcant proportion of patients particularly those with
positive symptoms [delusions and hallucinations] and when
used with high quality family psychotherapy input can
produce very enduring good outcomes (Leff et al., 1982).
However they don’t work in everyone, possibly because not
all patients with schizophrenia have a dopamine related
illness. For instance, a small subgroup of schizophrenics may
have undiagnosed rare diseases such as limbic encephalitis
(Martinez-Martinez et al., 2013).
One simple option for improvement in schizophrenia
treatment would be to stratify patients using biomarkers
that predict drug response. Very encouragingly, a genetic
variant was recently identiﬁed that very effectively predicts
response to lithium in Chinese bipolar patients (Chen et al.,
2014). To date, however we have failed to ﬁnd clinically
useful genetic predictors of antipsychotic response in schizo-
phrenia, despite intense research effort. Current evidence
from radioimaging studies reveals a subset of schizophrenia
patients that have excessive dopamine release to stimulants
(Laruelle et al., 1996) or increased dopamine turnover
(Fusar-Poli and Meyer-Lindenberg, 2013). Cheap and reliable
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brain dopamine excess could help direct interventions—and
those that do not show this should be the prime group in
which new treatments should be targeted.
Improving dopamine blockers is another tractable
approach, since we know what systems we are working
with. All current antipsychotics have adverse effects and
reﬁning medications to minimise these should be encour-
aged. This should include development of dopamine block-
ers with different proﬁles at other receptor systems e.g.
noradrenaline receptors (Litman et al., 1996) and new
partial agonists that may improve on the only current one,
aripiprazole.
Drugs that target the enhanced presynaptic dopamine
function seen in some patients, particularly in the pro-
drome, need to be considered. Here I (DJN) am reminded of
a patient seen many years ago whose schizophrenia symp-
toms improved remarkably for weeks after he had taken a
deliberate overdose of his antihypertensive medication
L-methyl-DOPA [Aldomet]. We presumed that this had effec-
tively depleted his synaptic pool of dopamine for a while, and
regret now never writing it up. Would a trial of this be
warranted?
5. A moonshot for clozapine?
The failure of current science to explain the unique
mechanism of action of clozapine is one of the most
humbling aspects of the current situation. Hundreds of
millions of dollars have been spent by pharmaceutical
companies and government research agencies on this pro-
blem with no conclusive outcomes. Most companies have
now given up the search as they pull out of brain research
altogether, and those that are left have much reduced
investment. However we know there must be a solution, so
how to ﬁnd it? An integrated network of researchers
spanning all aspects of neuroscience and clinical research
will be required, just as that which underpinned the
successful moonshots. In recent years we have seen speciﬁc
investments by both Europe and the USA in brain research in
an attempt to make signiﬁcant breakthroughs in conceptual
understanding [Human Brain Project https://www.human
brainproject.eu/en_GB]. The economic and human rewards
offered by cracking the clozapine question could be as great
and should be more tractable since the question is more
limited.
6. Back to the future?
Can we go back to the future and actively seek serendipity?
All the current drug classes we use in psychiatry were
discovered by astute clinical observation of unexpected
effects of drugs used to treat other disorders. In the case
of schizophrenia, chlorpromazine was found by testing – in
patients – of new sedative drugs. It took more than 5 years for
its mode of action (dopamine blockade) to be discovered.
Recently another potential treatment for schizophrenia has
been similarly found by accident. This is minocycline, an old
antibiotic that showed remarkable effects on schizophrenia
symptoms in two Japanese patients given it for life threaten-
ing infections (Dean et al., 2012). Since then there have beenseveral trials of it as an add-on to antipsychotic treatments
and results have been quite promising (Chaudhry et al.,
2012). We now need to work out why minocycline works. It
may be that some patients with schizophrenia have latent
infections but this seems unlikely. Minocycline has a range of
effects on microglia, glutamate systems and on neuroinﬂam-
mation, any of which might be signiﬁcant (Dean et al., 2012).
The use of serendipity to discover potential treatments
needs to be encouraged. Although well-established pro-
cesses for declaring adverse effects of drugs exist, the same
is not true for the reporting of beneﬁcial effects. Tradition-
ally this would have occurred as case reports but many
journals have now eliminated these as they reduce their
impact factor. So new avenues for reporting such cases need
to be developed. Case reports may be difﬁcult to publish in
journals, but a publically accessible web page could be used
to rapidly report and disseminate suspected antipsychotic,
antidepressant or anxiolytic effects of existing drugs, just as
they are for one-off associations of genetic variants with
disease (e.g., Decipher http://decipher.sanger.ac.uk/).
Such potential new therapeutic insights are unlikely to be
taken up by the pharmaceutical companies so other
approaches are required. Such studies could be modeled
on the open label ones such as those of Delay and Deniker
(1952) and Kuhn (1958) that identiﬁed the special properties
of chlorpromazine and imipramine i.e. in small well deﬁned
patient cohorts. National or international networks to allow
this should be set up and funded. Such expert centres would
also allow the training of the next generation of clinical
researchers.
Serendipity can also exist at the preclinical level. Some
drugs for other indications might have some impact in brain
disorders, particularly intracellular targets such as enzymes
and inﬂammatory modulators. However modern pharma-
ceutical research processes are very focused on single
diseases, and this usually precludes these compounds being
tested in models of brain function. Indeed many pharma-
ceutical companies now have no interest or in-house
expertise in brain pharmacology at all. If these drugs make
it to the clinic then they can be tested by others but if they
do not then they usually become extinct, a lamentable loss
of scientiﬁc knowledge and opportunity (Nutt et al., 2014).
At the very least these compounds should be put into the
public domain as soon as possible after they cease to be of
commercial value.7. Can genetics rise from the ashes?
It is clear that the genetics of schizophrenia is not going to be
simple, and most ﬁndings will not be rapidly clinically applic-
able, if at all. However there may be some exceptions. There
are currently several groups and consortia that are whole-
genome sequencing very large numbers of schizophrenia
patients, and we can expect one, and hope for a second,
important outcome. The ﬁrst is that some patients will have
causal mutations in genes that are already drug targets, and
these patients may respond to already approved treatments
that would never have been trialed for schizophrenia patients
otherwise. The second outcome, that many are pinning their
hopes on, is that a ‘new DRD2’ will be discovered. This is not
of course a literal hope for a new dopamine receptor, rather
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molecular pathway, which can be targeted either with new or
existing medications.
8. Improving back translation
The relevance of mutant mouse models may seem to be
diminished if any schizophrenia-associated genetic variant
either has only a miniscule additive effect on risk, or is seen
only in one or a few patients. Certainly the hope that a
mutant mouse could faithfully reproduce human psychiatric
disorders has always been an exercise more of faith than
certainty; mouse brains are signiﬁcantly different in size
and cortical structure, and schizophrenia diagnosis is based
on reports of symptoms that would be impossible to
measure in mice even if they could be recreated.
Mouse genetic models may nevertheless play a part in the
identiﬁcation of schizophrenia genes and their subsequent
guidance for treatments. With sample sizes in the tens or
hundreds of thousands, it is very likely that some genes will
be statistically demonstrated to have very highly penetrant
schizophrenia associated variants. However, there will be
many more genes that are not mutated in enough patients to
reach this threshold. With novel technologies such as CRISPR
(Terns and Terns, 2014), we can introduce known
schizophrenia-associated mutations in mice and look at their
effects on other gene products. Genes or gene products that
are explicitly affected by known schizophrenia-associated
mutations may have damaging mutations in other patients,
and these can be prioritized for targeted sequencing studies
in larger cohorts, expanding the list of statistically signiﬁcant
associated genes. Similarly, such mouse models can be used
to reveal novel molecular pathways that schizophrenia
mutations are converging on, and potentially identify our
hypothetical ‘new DRD2’ (Kapur and Mamo, 2003).
Mice (and rats) can also help us without being mutated.
The dopamine blocking actions of chlorpromazine were
discovered using simple pharmacological challenge tests in
rodents. Dopamine was enhanced by giving the precursor
L-dopa and a releaser amphetamine, and the subsequent
behavioural activation was blocked by chlorpromazine. All
other antipsychotics were validated with the same assays.
Such a simple screen allows us to test many thousands of
new compounds for the ability to decrease dopamine
hyperactivity. Some of these might work through novel
mechanisms i.e. other than by direct receptor blockade,
and could offer new approaches to treatment.
9. Encourage symptom targeting
If we can’t treat the disease of schizophrenia then at least we
can help reduce symptoms. This is what antipsychotics do;
they block dopamine D2 receptors and this somehow reduces
positive symptoms, possibly by altering the perceived sal-
ience of sensory inputs (Kapur, 2003). However, there are
many other symptoms in schizophrenia with cognitive and
motivational problems being prominent, and indeed the
major cause of disability. It is becoming accepted by reg-
ulatory bodies that approaching these with medicines is an
acceptable way to progress, though none has yet been
licensed. The challenges and methodologies for this approachto cognition in schizophrenia has recently been the subject of
a major consensus meeting (Nutt et al., 2013).
Similar approaches to negative symptoms are being
developed e.g. the use of amphetamines to enhance
motivation and reduce negative symptoms in patients
treated with antipsychotics (to prevent the positive symp-
toms worsening) (Lasser et al., 2013).
10. Look into the brain
Another approach that has been much touted is that of
measuring brain processes, particularly with imaging, to
identify schizophrenia-associated neural features, and then
trying to remedy them with new treatments. Such neural
features are known as ‘endophenotypes’ and are also
present in unaffected family members, who can be more
easily studied without the confounding effects of antipsy-
chotic treatments. The traditional theory of endopheno-
types is based on a threshold model, in which multiple
genetic variants contribute to schizophrenia in an additive
manner (Gottesman and Gould, 2003). Close relatives are
assumed to have many of the disease-associated alleles, but
not enough to 'push them over the edge' into disease.
However, in recent years it has been discovered that some
schizophrenia patients have single genetic variants that
have a very strong effect on disease risk, and thus do not
adhere to the threshold model. Despite their strong effects,
in some cases these variants are inherited from parents or
carried by siblings that do not have schizophrenia. These
unaffected carriers can have abnormalities similar to their
patient relatives that could be explored for drug response
(Spence et al., 2000). Of course the fact that they do not
have schizophrenia means that in some (as yet unknown)
ways their brains are different and the effect of this may
interfere with the results of the drug testing.
Humans, too, can be useful without being mutated. As for
mice, aspects of schizophrenia can be modeled in normal
healthy volunteers by giving them drugs that profoundly alter
their brain such as psychedelics, cannabis or ketamine (Carhart-
Harris et al., 2013). The challenge here is to ﬁnd medicines that
block the effects of these drug challenges without directly
interfering with the pharmacology of the challenge. So atypical
antipsychotics will block the effects of psychedelics just
because they block the 5HT2A receptors to which psychedelics
bind. Interesting new developments here include the use of MRI
measures of brain connectivity that are disrupted by drugs such
as psychedelics and ketamine in a similar fashion to that seen in
schizophrenia (Carhart-Harris et al., 2012). New agents e.g. a
tyrosine-kinase inhibitor, are currently being tested in this
model of schizophrenia (MRC/AstraZeneca: Mechanisms of
Disease Call assets, http://www.mrc.ac.uk/Fundingopportu
nities/Calls/MoD/compounds/index.htm) and if these work in
the lab – and then are validated in the clinic – this may prove a
useful way forward.
11. Conclusion
Schizophrenia remains a common and very damaging brain
disease that presents a serious challenge to neuroscience
and clinical therapeutics. The hoped-for advances that the
genetic revolution offered have not yet materialized, and
1185Where now for schizophrenia research?we remain, as ever, looking for answers that seem to lie just
round the next technological corner. Moreover, treatment
advances based on neuropathology and animal models of
glutamate dysfunction have also failed. We need now to
digest the implications of these disheartening ﬁndings and
develop new research strategies that will give succor to
research funders as well as the pharmaceutical industry and
give hope to patients and their families.
Some of these will involve more pragmatic and “mun-
dane” research and fewer theory-based approaches, and
the funding of these will require some changes in the way
research is viewed by funding agencies. For example,
structural funding sources could be used for setting up
new research centres. Others require the international
pooling of insights and data on the drugs that do work,
particularly clozapine, to develop newer safer alternatives.
For this to work there needs to be widespread buy-in from
funders, regulators and scientists. Dedicated funds to sup-
port serendipity might be made available e.g. to collect
data on positive but unexpected effects on schizophrenia
and related syndromes induced by other medicines (see the
recent report that warfarin might reduce symptoms http://
www.medscape.com/viewarticle/825210). These could be run
alongside national databases that collect information on the
adverse effects of medicines.
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